BioMarin Pharmaceutical Inc. · BMRN · FY2025 Q2 · Calendar Q3 2025
BioMarin pairs stronger Q2 growth and guidance with pipeline execution risks
BioMarin’s Q2 growth, raised full-year outlook and expanding rare-disease pipeline support a constructive operating picture. Whether this trajectory persists depends on sustaining product demand and converting clinical and regulatory milestones while managing safety and competitive risks.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about BMRN FY2025 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 16% year-over-year Q2 revenue growth and raised 2025 revenue, non-GAAP operating-margin and EPS guidance. The Inozyme acquisition added BMN 401 to the pipeline; management also described BMN 333 PK data and plans for a Phase II/III study in H1 2026.
Guidance delta
Raised full-year 2025 revenue, non-GAAP operating-margin and EPS guidance; the supplied analysis notes revenue guidance was raised to a low of $3.125 billion and operating-margin guidance to 33–34%.
Key takeaways
- Q2 revenue grew year over year, with VOXZOGO and enzyme therapies both cited as growth contributors.
- Management raised its full-year 2025 revenue, non-GAAP operating-margin and EPS outlook.
- The completed Inozyme acquisition added BMN 401; BMN 333 development is another pipeline focus.
- Current-quarter analysis points to safety, competition, regulatory timing and VOXZOGO guidance as areas to monitor.
Management priorities
- Expand VOXZOGO and PALYNZIQ through market access and label-expansion efforts.
- Advance BMN 333, BMN 401 and VOXZOGO hypochondroplasia development and regulatory work.
- Pursue additional business-development opportunities to diversify growth.
Follow BMRN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The company currently markets several key pharmaceutical products. Among these are Vimizim, an enzyme replacement therapy targeting mucopolysaccharidosis (MPS) IV type A, a specific lysosomal storage disorder, and Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for individuals with MPS VI. Another notable offering is Kuvan, a unique synthetic oral version of 6R-BH4, prescribed for phenylketonuria (PKU), an inherited metabolic condition. Further expanding its product portfolio, BioMarin provides Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme administered via subcutaneous injection to lower blood Phe levels.…
Historical context
All BMRN earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| JAZZ Jazz Pharmaceuticals plc | FY2026 Q3 · Calendar Q4 2026 | +4.2% | -0.7% | Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the BMRN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T10:40:44.261479+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T10:40:44.258659+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.